Gilead
FDA gives approval for Gilead’s hepatitis C therapy
July 19, 2017Research and Development, Sales and Marketing FDA, Gilead, US, Vosevi, biotech, drugs, healthcare, pharma, pharmaceutical
The FDA has announced that it has chosen to approve Vosevi (sofosbuvir/velpatasvir/voxilaprevir), Gilead’s investigational drug for the treatment of chronic …
Gilead to launch injunction against Mylan and Actavis over HIV generics in Ireland
July 6, 2017Sales and Marketing Actavis, Gilead, HIV, Mylan, Truvada
Gilead is expected to launch injunctive action against rivals Mylan and Actavis over the allegation that they are planning to …
Amygdala acquires Gilead’s candidate for addiction treatment
February 20, 2017Manufacturing and Production, Sales and Marketing Amygdala, Gilead
Amygdala Neurosciences, a biopharmaceutical company that develops and commercialises drugs for the treatment of addiction disorders, has agreed an acquisition …
Hepatitis C market set for slump as cure rates rise
February 14, 2017Manufacturing and Production, Medical Communications, Sales and Marketing Gilead, hepatitis C
Objectively, it is the pharmaceutical industries intention to find cures for diseases and to aid patients to live a full …
Gilead makes move in oncology by snaffling Riva from Novartis
January 4, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, Novartis, oncology
Gilead Sciences have made an ambitious move to boost its oncology business by appointing current head of global oncology development …
Court of Appeal rules that the NHS can legally fund HIV-prevention drug PrEP
November 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Court of Appeals, Gilead, NHS England, Truvada, high court
A High Court ruling that NHS England was legally responsible for preventing the spread of HIV has been upheld when …
Gilead quietly drops drugs from line up alongide Q3 results
November 2, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abzena, Gilead, research and development
Gilead Sciences followed Pfizer in discreetly dropping a drug alongside its third quarter profit reports. The drug in question, for …
Gilead’s drug boosted by positive Phase II trials and aims to move forward
October 21, 2016Medical Communications Gilead, Gilead Sciences, clinical trials, fatty liver disease
Gilead Sciences has announced positive results from three Phase II studies upon their drug GS-4997, otherwise known as selonsertib. The …
Gilead terminates Phase II/III study for ulcerative colitis antibody
September 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, ulcerative colitis
Gilead has put the brakes on a Phase II/III study of its anti-MMP9 antibody GS-5745 for the treatment of ulcerative …
Top Ten articles in the Pharma Industry this week
September 16, 2016Medical Communications Bayer, GSK, Gilead, GlaxoSmithKline, J&J, JJ, Pfizer, Roche, Sanofi, Takeda, aspen, google, monsanto
As we come to the end of another week, we’re looking back at an exciting week in the industry; there …
Gilead appoints former Roche executive
September 9, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, Roche, appointment
Gilead Sciences has hired Rogers Luo as vice president and general manager of commercial operations in China. Luo formerly served …
Gilead gets EU approval for HIV-prevention treatment Truvada
August 23, 2016Manufacturing and Production, Sales and Marketing EU, Gilead, HIV, PrEP, Truvada, prevention
Gilead Sciences has received marketing authorisation from the European Commission for once-daily Truvada (emtricitabine/tenofovir disoproxil), in combination with safer sex …
Gilead to work with Genmab on HIV targeting technology
August 12, 2016Medical Communications, Research and Development, Sales and Marketing Genmab, Gilead, HIV, duobody
Genmab has announced that it has entered into a collaboration deal with Gilead Sciences to use the DuoBody technology platform …
Gilead lowers full-year guidance as sales and profits down in Q2
July 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing 2016, Gilead, Q2, results
Gilead Sciences has announced its financial results from the second quarter of this year, with sales and profits taking a …
AbbVie scores EU recommendation for shorter treatment of Viekirax in hepatitis C
July 25, 2016Research and Development, Sales and Marketing EU, Gilead, Viekirax, hepatitis C
AbbVie has received an EU recommendation for a shorter treatment duration of Viekirax (ombitasvir/paritaprevir/ritonavir) plus ribavirin in genotype 4 chronic …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
